Abstract

The Nuvaxovid vaccine, developed by the firm Novavax, a recombinant protein vaccine (NVX-CoV2373 vaccine) against COVID-19 which uses the Spike protein of wild-type SARS-CoV-2 (Wuhan strain) associated with the Matrix-M adjuvant, is indicated for primary vaccination in persons aged 18 years and over.

  • Recommendation
  • Europe
  • France
  • COVID-19